Evaluation of the long-term cost-effectiveness of insulin detemir compared with neutral protamine hagedorn insulin in patients with type 1 diabetes using a basal-bolus regimen in Sweden
The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Abstract
Aims: To evaluate the long-term clinical and economic outcomes associated with insulin detemir and neutral protamine hagedorn (NPH) insulin in combination with mealtime insulin aspart in patients with type 1 diabetes in Sweden, based on data from a two-year, multi-national, open-label, randomized, controlled trial. Methods: Insulin detemir was associated with significant improvements in glycaemic control after 24 months (HbA1c 7.36% versus 7.58%, mean difference -0.22%, p = 0.022) and major hypoglycaemic events (69% risk reduction, p = 0.001) versus NPH. Patients treated with detemir gained less weight (1.7 versus 2.7 kg, P = 0.024). Based on these findings, a published and validated computer model (IMS CORE Diabetes Model) was used to estimate life-expectancy, quality-adjusted life expectancy and both direct medical costs and indirect costs. Results: Basal-bolus therapy with insulin detemir was projected to improve life expectancy by 0.14 years (15.02 ± 0.19 versus 14.88 ± 0.18 years) and quality-adjusted life expectancy by 0.53 quality-adjusted life years (QALYs) versus NPH (8.35 ± 0.11 versus 7.82 ± 0.10 QALYs). Improvements in QALYs were driven by avoided or delayed diabetes-related complications and fewer hypoglycaemic events. Direct medical costs over patient lifetimes were SEK 26,144 higher in the insulin detemir arm (SEK 995,025 ± 19,580 versus 968,881 ± 19,769), leading to an incremental cost-effectiveness ratio of SEK 49,757 per QALY gained. Capturing indirect costs led to insulin detemir being cost saving over patient lifetimes, by SEK 80,113, compared to NPH (SEK 2,959,909 ± 64,727 versus 3,040,022 ± 62,317). Conclusions: Compared with NPH, insulin detemir is likely to be cost-effective from a healthcare payer perspective and dominant from a societal perspective in patients with type 1 diabetes in Sweden.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The UKPDS risk engine: a model for the risk of coronary heart disease in Type II diabetes (UKPDS 56)
STEVENS, R. J., KOTHARI, V., ADLER, A. I., & STRATTON, I. M. (2001) · Clinical Science · doi:10.1042/cs20000335 · Cited by 1,084 · cited 1×
“This is in line with published data indicating the BMI is not an independent risk factor for most macrovascular complications in diabetes patients (however, blood pressure and serum lipid levels are often captured) [26,27].”
ResultIncidence of childhood type 1 diabetes worldwide. Diabetes Mondiale (DiaMond) Project Group
Karvonen, M., Viik-Kajander, M., Moltchanova, E., Libman, I., LaPorte, R., & Tuomilehto, J. (2000) · Diabetes Care · doi:10.2337/diacare.23.10.1516 · Cited by 1,072
Hermansen, K., Fontaine, P., Kukolja, K. K., Peterkova, V., Leth, G., & Gall, M.-A. (2004) · Diabetologia · doi:10.1007/s00125-004-1365-z · Cited by 365
Vague, P., Selam, J.-L., Skeie, S., De Leeuw, I., Elte, J. W. F., Haahr, H., Kristensen, A., & Draeger, E. (2003) · Diabetes Care · doi:10.2337/diacare.26.3.590 · Cited by 294
Psychological status of diabetic people with or without lower limb disability
Carrington, A. L., Mawdsley, S. K. V., Morley, M., Kincey, J., & Boulton, A. J. M. (1996) · Diabetes Research and Clinical Practice · doi:10.1016/0168-8227(96)01198-9 · Cited by 201
Russell-Jones, D., Simpson, R., Hylleberg, B., Draeger, E., & Bolinder, J. (2004) · Clinical Therapeutics · doi:10.1016/s0149-2918(04)90072-0 · Cited by 194 · cited 1×
“study are consistent with a number of other trials of insulin detemir versus NPH [9,29,30].”
ResultBartley, P. C., Bogoev, M., Larsen, J., & Philotheou, A. (2008) · Diabetic Medicine · doi:10.1111/j.1464-5491.2007.02407.x · Cited by 159 · cited 6×
“0 [10] Duration of diabetes (years) 13.”
BackgroundMethodInfluential
Cited by
Tricco, A. C., Ashoor, H. M., Antony, J., Beyene, J., Veroniki, A. A., Isaranuwatchai, W., Harrington, A., Wilson, C., Tsouros, S., Soobiah, C., et al. (2014) · BMJ · doi:10.1136/bmj.g5459 · Cited by 117
(Ultra-)long-acting insulin analogues for people with type 1 diabetes mellitus
Hemmingsen, B., Metzendorf, M.-I., & Richter, B. (2021) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd013498.pub2 · Cited by 37
Lee, T., Kuo, S., Yang, C., & Ou, H. (2020) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.14188 · Cited by 18
“Second, the projection of long-term outcomes (eg, incidence of diabetes-related complications) is usually done using short-term results based on clinical biomarkers (eg, HbA1c) due to a lack of effectiveness data from real-world settings.(17-25) However, the extrapolation from clinical biomarkers to clinical events in…”
BackgroundMethod
Metadata
- Authors
- Valentine, W. J., Aagren, M., Haglund, M., Ericsson, Å., & Gschwend, M. H.
- Venue
- Scandinavian Journal of Public Health
- Publisher
- SAGE Publications
- Published
- 2010-08-05
- Volume
- 39
- Issue
- 1
- Pages
- 79-87
- ISSN
- 1403-4948 (ISSN-L)
- 1651-1905
- OpenAlex
- W1994398288
- Cited by
- 34
- References
- 7
- FWCI
- 1.54
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Evaluation of the long-term cost-effectiveness of insulin detemir compared with neutral protamine hagedorn insulin in patients with type 1 diabetes using a basal-bolus regimen in Sweden. https://app.cochat.ai/papers/10.1177/1403494810379290
- The paper
- Valentine, W. J., Aagren, M., Haglund, M., Ericsson, Å., & Gschwend, M. H. (2011). Evaluation of the long-term cost-effectiveness of insulin detemir compared with neutral protamine hagedorn insulin in patients with type 1 diabetes using a basal-bolus regimen in Sweden. Scandinavian Journal of Public Health. https://doi.org/10.1177/1403494810379290
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.